Abiomed® is committed to leading in technology and innovation, and improving patient outcomes by developing smaller, smarter and more connected technology.

Core values

- **Addressing Healthcare Disparities**: Abiomed has established the W. Gerald Austen Disparities in Healthcare Initiative to reduce treatment disparities, particularly benefiting non-Caucasian high-risk PCI patients and those in underserved communities[1].
- **Improving Clinical Outcomes**: The use of Impella heart pumps has been shown to significantly improve clinical outcomes for patients with heart failure, cardiogenic shock, and right heart failure, as evidenced by numerous clinical trials and real-world data[1][4].
- **Enhancing Quality of Life**: A significant proportion of patients treated with Impella heart pumps experience a reduction in heart failure symptoms or improved ejection fraction, which enhances their quality of life[3].
- **Commitment to Research**: Abiomed has invested heavily in clinical research, with over $850 million spent in the last five years, which contributes to the development of safe and effective treatments and improves patient outcomes[4].